8-K: Verastem Oncology Announces Positive Updated Results from RAMP 205 Trial in Metastatic Pancreatic Cancer

Verastem Oncology reports promising updated data from its RAMP 205 trial, showing an 83% overall response rate in frontline metastatic pancreatic cancer patients treated with avutometinib and defactinib in combination with standard chemotherapy.

Summary

• Verastem Oncology announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial.
• The trial evaluated avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in patients with frontline metastatic pancreatic ductal adenocarcinoma (PDAC).
• As of April 25, 2025, the dose level 1 cohort achieved an overall response rate (ORR) of 83% (10/12).
• Dose level 1 has been selected as the recommended Phase 2 dose (RP2D).
• The company plans to begin a registrational Phase 3 trial in frontline metastatic PDAC in 2026.
• Verastem will host an investor webcast on June 2, 2025, to review the RAMP 205 data and the VS-7375 program.
• The FDA approved AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) on May 8, 2025.
• Verastem is also evaluating avutometinib in combination with defactinib and other agents as a potential treatment for patients with advanced pancreatic cancer and advanced KRAS G12C mutant non-small cell lung cancer.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and plans for further development, indicating a favorable outlook for the company and its pipeline.

Positives

• High overall response rate (83%) in the dose level 1 cohort of the RAMP 205 trial.
• Significant tumor reduction observed in a high percentage of patients (92%).
• Advancement to the expansion stage of the RAMP 205 study.
• Plans for a registrational Phase 3 trial in 2026.
• FDA approval of AVMAPKI FAKZYNJA CO-PACK for LGSOC.
• Initiation of a Phase 1/2a clinical trial for VS-7375 is planned for mid-2025.

Negatives

• The document mentions potential ocular toxicities, serious skin toxicities, hepatotoxicity, rhabdomyolysis, and embryo-fetal toxicity associated with AVMAPKI FAKZYNJA CO-PACK.
• The document mentions that continued approval for the LGSOC indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Risks include the possibility of negative or unexpected results of clinical trials.
• There are risks associated with preliminary and interim data, which may not be representative of more mature data.
• The development and commercialization of product candidates may take longer or cost more than planned.
• Product candidates may not receive regulatory approval or become commercially successful.

Future Outlook

The company is developing plans for a registrational Phase 3 front-line metastatic PDAC trial to begin in 2026 and plans to initiate a Phase 1/2a clinical trial for VS-7375 in mid-2025.

Management Comments

• Dan Paterson, president and chief executive officer of Verastem Oncology, stated that the results from the RAMP 205 trial reinforce the company's commitment to maximizing the synergistic potential of the avutometinib plus defactinib combination.
• Dan Paterson also mentioned looking forward to the mature data from the Phase 1 portion of the VS-7375 study in China and dosing the first patient in the Phase 1/2a trial in the U.S.

Industry Context

This announcement is significant in the context of pancreatic cancer treatment, as new therapies are urgently needed to improve outcomes for patients with this aggressive disease; the high response rate observed in the RAMP 205 trial suggests a potential advancement in the treatment landscape.

Comparison to Industry Standards

• The 83% ORR in the dose level 1 cohort of the RAMP 205 trial is a promising result compared to historical response rates for first-line treatment of metastatic pancreatic cancer, which typically range from 20-30% with standard chemotherapy regimens like gemcitabine and nab-paclitaxel.
• Companies like Eli Lilly (Gemzar), Celgene/Bristol Myers Squibb (Abraxane), and others have established chemotherapy regimens as standard of care, but Verastem's combination therapy shows potential for improved efficacy.
• Other companies such as Novartis, Roche, and Amgen are also developing targeted therapies for pancreatic cancer, but Verastem's approach of combining MEK and FAK inhibitors represents a unique strategy.
• The recent FDA approval of AVMAPKI FAKZYNJA CO-PACK for LGSOC provides a precedent for the potential regulatory pathway for this combination therapy in other cancer types.

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with pancreatic cancer.
• Successful development and commercialization of new therapies could increase shareholder value.
• The company's employees may benefit from the company's growth and success.

Next Steps

• Enrollment of up to 29 patients at dose level 1 in the expansion study.
• Development of plans for a registrational Phase 3 front-line metastatic PDAC trial to begin in 2026.
• Initiation of a Phase 1/2a clinical trial for VS-7375 in mid-2025.
• Presentation of VS-7375 data at the ASCO Annual Meeting on June 2, 2025.
• Investor webcast on June 2, 2025, to review RAMP 205 data and the VS-7375 program.

Key Dates

Keywords

Verastem Oncology, RAMP 205, Avutometinib, Defactinib, Pancreatic Cancer, Metastatic PDAC, VS-7375, KRAS G12D, Clinical Trial, FDA Approval, LGSOC